The association between HLA and non-Hodgkin lymphoma subtypes, among a transplant-indicated population
Charlie Zhong(City of Hope), Sophia Wang(City of Hope), Joo Y. Song(City Of Hope National Medical Center), Loren Gragert(Tulane University), Martin Maiers(National Marrow Donor Program), Jean Garcia-Gomez(City of Hope), Leanne Goldstein(City of Hope), David Senitzer(City of Hope), Brian T. Hill(Cleveland Clinic), Ketevan Gendzekhadze(City Of Hope National Medical Center), Dennis D. Weisenburger(University of Nebraska Medical Center)
Cited by 13
Related Papers
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
|Nature|2000|10k
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k